Peptide·plain sequence-like

Oxytocin

ATLPC0018730

CYIQNCPLG

Routes

Compare in workbench Download release API JSON

Length
9 aa
Monoisotopic mass
1009.4 Da
Net charge @ pH 7.4
0.00
Isoelectric point
5.82
GRAVY
0.333

Coveragecounts only · not riskATLPC0018730

Measurements
20
Endpoints
7
Domains
3/5
Products
1

No matrix stability evidence
8 clearance measurements
2 immunogenicity context entries
2 liability motifs

Jump to domain

Open the matching evidence section below

All evidence index · 20

Exposure / Absorption

3 measurements

Distribution / Barrier

9 measurements

Metabolic & Proteolytic Stability

No evidence

Excretion / Persistence

8 measurements

Toxicity / Safety

No evidence

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

Sequence & peptidoform

Identity summaryCanonical sequence only

Identity status: Canonical sequence only
Residues: 9
Peptidoform features: 0
Documented molecular forms: 1
Representations: 2

Documented molecular forms1 form linked to this peptide identity

Form	Topology	Modifications	Connections	Representations	Measurements
ATLPF0020449	—	1	—	Notation only	6

Residue view

Residue display

9 residues

C1Y2I3Q4N5C6P7L8G9

Secondary structureα-helix (H)β-strand (E)coil (C)

Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

No terminal modification, residue-level marker, disulfide, staple, coordination, or other topology signal is currently available.

Structure & chemistry

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

plain sequence-like

Parent-residue sequence

Residue string used for positional interpretation when available.

CYIQNCPLG

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure references2 references

Structure reference·

3D coordinates·Exact PDB matchexperimental

Exact PDB match·reference selected·length 9 aa·confidence experimental

Link	Method	Confidence	Match
Open	Experimental coordinate entry	experimental	9 aa
Open	Experimental coordinate entry	experimental	9 aa

Covalent topology & modificationsnone

Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

Physicochemical profile

4 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Core descriptors9 aa · pI 5.8 · GRAVY 0.33

Length: 9 aa
Monoisotopic mass: 1009.44 Da
Average mass: 1010.19 Da
Net charge at pH 7.4: 0.00
Estimated pI: 5.82
GRAVY: 0.333
KD-positive residues: 44.4%
Aromatic residues: 11.1%

Developability interpretation

Ionization context: pH 7.4 separated from pI
Hydrophobicity balance: Leans hydrophobic
Amphipathic moment (μH): 0.40
Computation boundary: Standard-sequence only

Charge & residue composition

pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2

0.98

pH 5

0.04

pH 6

0.00

pH 7.4

-0.21

pH 9

-2.31

pH 12

-3.99

Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Polar uncharged (N,Q,S,T)

2 · 22.2%

Hydrophobic aliphatic (A,V,I,L,M)

2 · 22.2%

Aromatic (F,W,Y)

1 · 11.1%

Conformational / sulfur (G,P,C)

4 · 44.4%

Top residues

C222.2%N111.1%Q111.1%G111.1%I111.1%L111.1%P111.1%Y111.1%

Hydropathy & amphipathic windows

Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window

3-9

IQNCPLG

GRAVY 0.257

Most hydrophilic window

1-7

CYIQNCP

GRAVY -0.057

3 local hydropathy windows scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.

Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

Sequence is shorter than the local amphipathic-window sizes used here.

Sequence-liability cues

Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Oxidation-sensitive residues

C · pos 1, 6

Met, Trp, and Cys residues can merit formulation review for oxidation or covalent-state sensitivity.

Cys covalent complexity

C · pos 1, 6

Multiple cysteines can indicate disulfide or free-thiol interpretation requirements.

Alpha-helix amphipathic projection

Helical wheel · Edmundson projection

μ_H = 0.40100°/residue · 9 aa

Hydrophobic moment0.40

Mean K-D hydropathy0.33

Approx. net charge0

Projection angle100° / residue

The pale sector marks the direction of the hydrophobic face inferred from μ_H. This is a projection assumption, not a measured fold.

HydrophobicAromaticPolarBasic +Acidic −Specialhydrophobic faceμ_H arrow → hydrophobic face

The projection assumes an α-helix conformation; a long μ_H arrow indicates an amphipathic helix, common in antimicrobial peptides.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Sequence-derived

Computed from the standard parent-residue sequence; protein-origin metrics defined at any length.

Aliphatic index

86.67

Instability index

27.1

At or below 40 — predicted stable in vitro.

Boman index

-0.11 kcal/mol

Molar extinction coefficient (280 nm)

1,490 M⁻¹·cm⁻¹

A280 (1 g/L) ≈ 1.48 · 1,615 M⁻¹·cm⁻¹ with 1 disulfide

Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.

Exposure / Absorption

3 records

What evidence describes systemic exposure or absorption?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeBioavailability Tmax

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Bioavailability2 records · 1 matched-context · 1 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	0.85 %	Eligible when experimental context matches	Oral bioavailability in rat · rat	Result: Reported point value · Molecular form: not reported · Route: oral · bioavailability · F· Oral bioavailability in rat · Exact ChEMBL pref name OXYTOCIN · http... · Source: Primary reference linked	Reference
2	0.007-0.07 %	Use only explicitly reported fields	Not specified	Result: Interval measurement · Molecular form: not reported · Route: SL · 2 · Oxytocin · exact product name match · exact or normalized match · Source: Primary reference linked	Source record

Tmax1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	~= 40 min ~= 2400 seconds	Eligible when experimental context matches	Manual extraction from PubMed-indexed clinical PK abstract; plasma oxytocin sampling during labor-augmentation infusion · human · plasma	Result: Approximate quantitative measurement · Molecular form: not reported · Route: intravenous infusion · Dose/window: labor augmentation infusion; 1 mU/min initial dose; 1 mU/min increments every 4... · Time: approximately 40 min after each dose step · Source: Primary reference linked	Reference

Distribution / Barrier

9 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopePlasma protein binding BBB penetration Vd

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Vd1 record · 1 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	33.2 L	Eligible when experimental context matches	Manual extraction from PubMed-indexed clinical PK abstract; two-compartment model after IV oxytocin · human · plasma	Result: Reported point value · Molecular form: not reported · Route: intravenous · Source: Primary reference linked	Reference

Plasma protein binding1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	30 %	Use only explicitly reported fields	plasma protein	Result: Reported point value · Molecular form: not reported · Route: IV, IM · 2 · Oxytocin · exact product name match · exact or normalized match · Source: Primary reference linked	Source record

BBB penetration7 records · 3 matched-context · 4 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	0.00815 mL/g	Eligible when experimental context matches	Intracarotid injection · blood-brain barrier	Result: Reported point value · Molecular form: not reported · VD · Source: Primary reference linked	Reference
2	0.018 %/g	Eligible when experimental context matches	Intravenous injection · blood-brain barrier	Result: Reported point value · Molecular form: not reported · % injected dose · Source: Primary reference linked	Reference
3	1.09 μL/g/min	Eligible when experimental context matches	Intravenous injection · blood-brain barrier	Result: Reported point value · Molecular form: not reported · PS · Source: Primary reference linked	Reference
4	0.00815 mL/g	Interpret as reported	NA · NA · blood-brain barrier	Result: Reported point value · Molecular form: not reported · Route: Intracarotid injection · Permeability · Source: Primary reference linked	Reference
5	0.018 %/g	Interpret as reported	NA · NA · blood-brain barrier	Result: Reported point value · Molecular form: not reported · Route: Intravenous · Permeability · Source: Primary reference linked	Reference
6	1.09 μL/g/min	Interpret as reported	NA · NA · blood-brain barrier	Result: Reported point value · Molecular form: not reported · Route: Intravenous · Permeability · Source: Primary reference linked	Reference
7	Observation transport_type: Permeability	Interpret as reported	Not specified	Result: Qualitative or narrative result · Molecular form: not reported · Source: Primary reference linked	Reference

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

artificial membrane

Caco-2

cell monolayer

MDCK

cell monolayer

RRCK

cell monolayer

BBB

barrier evidence

Excretion / Persistence

8 records

What evidence describes clearance or persistence?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeHalf Life Clearance

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Clearance2 records · 1 matched-context · 0 as reported · 0 context only · 1 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	21 mL/min/kg	Eligible when experimental context matches	Clearance in Sprague-Dawley rat at 0.2 mg/kg, iv administered in cassette mode as bolus dose · rat	Result: Reported point value · Molecular form: not reported · Route: iv · clearance · CL· Clearance in Sprague-Dawley rat at 0.2 mg/kg, iv administered in cassette... · Source: Primary reference linked	Reference
2	7.87 mL/min	Review experimental context before comparison	Not specified	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference

Half Life6 records · 3 matched-context · 1 as reported · 0 context only · 2 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	1 days 86400 seconds	Eligible when experimental context matches	HPLC and LC/ITMS · Bacterial strain B-9 cell culture	Result: Reported point value · Molecular form: ATLPF0020449 · Dose/window: 1mg/mL · Time: Room Temperature · Hydolytic activity of bacterial strain B-9 · in vitro · Source: Primary reference linked	Reference
2	systemic pk half life unspecified phase: 0.5 Hours 1800 seconds	Eligible when experimental context matches	LC-MS/MS · mouse · C57BL/6J mice plasma	Result: Reported point value · Molecular form: ATLPF0020449 · Route: SC · Dose/window: 10 ml/kg · Time: Time points postdose: 0.25 (OT only), 0.5, 1, 2, 4, 6, and 24 hours (6- and 24-hour sampling limited to PF1 o... · C57Bl/6J mice plasma protease · In Vivo · Source: Primary reference linked	Reference
3	systemic pk half life unspecified phase: 0.12 Hours 432 seconds	Eligible when experimental context matches	LC-MS/MS · rat · Wistar rats plasma	Result: Reported point value · Molecular form: ATLPF0020449 · Route: IV · Time: Time points postdose: 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 7, and 24 hours · Wistar rats plasma protease · In Vivo · Source: Primary reference linked	Reference
4	systemic pk half life unspecified phase: 7.3 Hours 26280 seconds	Use only explicitly reported fields	LC-MS/MS · mouse · C57BL/6J mice plasma	Result: Reported point value · Molecular form: ATLPF0020449 · Route: SC · C57Bl/6J mice plasma protease · In Vivo · Source: Primary reference linked	Reference
5	6.78 minutes 406.8 seconds	Review experimental context before comparison	Not specified	Result: Reported point value · Molecular form: ATLPF0020449 · Source: Primary reference linked	Reference
6	6.78 minutes 406.8 seconds	Review experimental context before comparison	Not specified	Result: Reported point value · Molecular form: ATLPF0020449 · Source: Primary reference linked	Reference

Evidence landscape

20 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain

Eligible when context matches

Interpret as reported

Supporting context only

Review before analysis

Exposure / Absorption

3 evidence records

Distribution / Barrier

9 evidence records

Metabolic & Proteolytic Stability

0 evidence records

Excretion / Persistence

8 evidence records

Toxicity / Safety

0 evidence records

Endpoint distribution

Top evidence-bearing endpoint questions.

Blood Brain Barrier Penetration

Half Life

Bioavailability

Clearance

Plasma Protein Binding

Time To Max Concentration

Volume Of Distribution

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Matrix / stability

Unspecified

Clinical / product

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainAnalysis useReferenceSpeciesMatrixRoute

#	ADMET domain	Endpoint	Reported value	Result type	Analysis use	Assay / model	Condition	Reference
1	Excretion / Persistence Persistence	Half Life	6.78 minutes 406.8 seconds	Reported point value	Review experimental context before comparison	Not specified	Not specified	Reference Primary reference linked
2	Excretion / Persistence Persistence	Half Life	6.78 minutes 406.8 seconds	Reported point value	Review experimental context before comparison	Not specified	Not specified	Reference Primary reference linked
3	Excretion / Persistence Persistence	Half Life	0.12 Hours 432 seconds Result metric: SYSTEMIC_PK_HALF_LIFE_UNSPECIFIED_PHASE	Reported point value	Eligible when experimental context matches	LC-MS/MS · rat · Wistar rats plasma	Route: IV · Time: Time points postdose: 0.033, 0.083, 0.25, 0.5, 1, 2, 4, 7, and 24 hours · Protease: Wistar rats plasma protease · In Vivo	Reference Primary reference linked
4	Excretion / Persistence Persistence	Half Life	7.3 Hours 26,280 seconds Result metric: SYSTEMIC_PK_HALF_LIFE_UNSPECIFIED_PHASE	Reported point value	Use only explicitly reported fields	LC-MS/MS · mouse · C57BL/6J mice plasma	Route: SC · Protease: C57Bl/6J mice plasma protease · In Vivo	Reference Primary reference linked
5	Excretion / Persistence Persistence	Half Life	1 days 86,400 seconds	Reported point value	Eligible when experimental context matches	HPLC and LC/ITMS · Bacterial strain B-9 cell culture	Time: Room Temperature · Dose/window: 1mg/mL · Protease: Hydolytic activity of bacterial strain B-9 · in vitro	Reference Primary reference linked
6	Excretion / Persistence Persistence	Half Life	0.5 Hours 1,800 seconds Result metric: SYSTEMIC_PK_HALF_LIFE_UNSPECIFIED_PHASE	Reported point value	Eligible when experimental context matches	LC-MS/MS · mouse · C57BL/6J mice plasma	Route: SC · Time: Time points postdose: 0.25 (OT only), 0.5, 1, 2, 4, 6, and 24 hours (6- and 24-hour sampling limited to PF1 only · Dose/window: 10 ml/kg · Protease: C57Bl/6J mice plasma p...	Reference Primary reference linked
7	Excretion / Persistence Persistence	Clearance	7.87 mL/min	Reported point value	Review experimental context before comparison	Not specified	Not specified	Reference Primary reference linked
8	Distribution / Barrier Distribution	Plasma Protein Binding	30 %	Reported point value	Use only explicitly reported fields	plasma protein	Route: IV, IM	Source record Primary reference linked
9	Exposure / Absorption Exposure	Bioavailability	0.007-0.07 %	Interval measurement	Use only explicitly reported fields	Not specified	Route: SL	Source record Primary reference linked
10	Excretion / Persistence Persistence	Clearance	21 mL/min/kg	Reported point value	Eligible when experimental context matches	Clearance in Sprague-Dawley rat at 0.2 mg/kg, iv administered in cassette mode as bolus dose · rat	Route: iv · chembl_activity_endpoint_review_v0_1 · ChEMBL molecule_type Protein	Reference Primary reference linked

1–10 / 20

Product context

1 products

Product-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.

Summary1 linked product

Linked products: 1
Label context: 1
Clinical trials: 29
Safety label cues: 5

Linked products1 shown

Oxytocin

Peptide-product match

Unique peptide match

Route / product class

Intravenous infusion · Oxytocics, Anti-tocolytic Agents and Labor Induction Agents

Clinical context

29 trial records · 12 exact intervention matches · 5 with results · latest 2026-01-05

Label safety context

Label linked · Contraindications · Adverse reactions · Clinical AE review · Immunogenicity review

View product

Identity & reference map

20 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

Summary12 reference groups

Identity type: canonical sequence
Reported notation: 1
Reference groups: 12
Measurements: 20
ATL peptide ID: ATLPC0018730

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 20

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 20

Different notation

Reported notation does not resolve to the current display sequence.

2 / 20

Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

18 / 20

Reported sequence notation

Different2 references

CYIQNCPLG-NH2

Current identity

CYIQNCPLG

Reported names

No distinct human-readable aliases are exposed.

Reference map12 reference groups

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference Open	Distribution Blood Brain Barrier Penetration	No reported alias	6 identity 6 evidence
Reference Open	Persistence Half Life	No reported alias	2 identity 2 evidence
Reference Open	Persistence Half Life	No reported alias	2 identity 2 evidence
Source record Open	DistributionExposure Bioavailability, Plasma Protein Binding	No reported alias CYIQNCPLG-NH2different	2 identity 2 evidence
Reference Open	Distribution Blood Brain Barrier Penetration	No reported alias	1 identity 1 evidence
Reference Open	Persistence Half Life	No reported alias	1 identity 1 evidence
Reference Open	Persistence Half Life	No reported alias	1 identity 1 evidence
Reference Open	Persistence Clearance	No reported alias	1 identity 1 evidence
Reference Open	Persistence Clearance	No reported alias	1 identity 1 evidence
Reference Open	Exposure Bioavailability	No reported alias	1 identity 1 evidence

1–10 / 12

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

Record scopePublic release

ATL peptide ID: ATLPC0018730
Identity type: canonical sequence
ADMET endpoints: 7
Evidence records: 20
Reference groups: 12
Release view: Public release

Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements

Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint

GET /api/v1/peptides/ATLPC0018730

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0018730' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Form

Topology

Modifications

Connections

Representations

Measurements

ATLPF0020449

—

Notation only

Link

Method

Confidence

Match

Open

Experimental coordinate entry

experimental

9 aa

Open

Experimental coordinate entry

experimental

9 aa

Value

Analysis use

Assay / model

Result context

Reference

0.85 %

Eligible when experimental context matches

Oral bioavailability in rat · rat

Result: Reported point value · Molecular form: not reported · Route: oral · bioavailability · F· Oral bioavailability in rat · Exact ChEMBL pref name OXYTOCIN · http... · Source: Primary reference linked